Protagonist Therapeutics (NASDAQ:PTGX) vs. Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Head-To-Head Comparison

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, profitability and earnings.

Profitability

This table compares Lakefront Biotherapeutics American Depositary Shares and Protagonist Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Protagonist Therapeutics	29.40%	12.03%	11.23%

Institutional & Insider Ownership

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500.

Valuation & Earnings

This table compares Lakefront Biotherapeutics American Depositary Shares and Protagonist Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26 billion	1.64	$363.05 million	($1.41)	-22.27
Protagonist Therapeutics	$46.02 million	196.01	-$130.15 million	$1.03	135.34

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Protagonist Therapeutics. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Lakefront Biotherapeutics American Depositary Shares and Protagonist Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0	5	3	0	2.38
Protagonist Therapeutics	0	0	16	2	3.11

Lakefront Biotherapeutics American Depositary Shares presently has a consensus price target of $35.50, suggesting a potential upside of 13.06%. Protagonist Therapeutics has a consensus price target of $158.19, suggesting a potential upside of 13.48%. Given Protagonist Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Protagonist Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Summary

Protagonist Therapeutics beats Lakefront Biotherapeutics American Depositary Shares on 13 of the 15 factors compared between the two stocks.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.